Wilson Sonsini Goodrich & Rosati advised SR One Capital Management on the deal. ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA targeting therapeutics, announced the completion...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Logos Capital on the deal while Sidley represented Attralus, Inc. Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised SR One on the deal. ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Tybourne Capital Management on the deal. Zentera Therapeutics, a clinical-stage biopharmaceutical company, completed a $75 million Series B financing. Founding investors...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Aristea Therapeutics on the deal. Arena Pharmaceuticals, Inc. and Aristea Therapeutics, Inc. announced a strategic collaboration to advance the clinical...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Aristea Therapeutics on the deal. Aristea announced the closing of a $63 million Series B financing led by Fidelity Management &...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Versant Ventures and NEA on the deal. Stablix Therapeutics announced a $63 million Series A financing. The funding round was...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Arcellx on the deal. Arcellx, a privately held clinical-stage biopharmaceutical company, announced that it raised $115 million in a Series...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Vividion Therapeutics, Inc. and the lead investors on the deal. Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies...
You must be a Standard 1 Year member to access this content.
